S
Swati Garg
Researcher at Princess Margaret Cancer Centre
Publications - 17
Citations - 431
Swati Garg is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Serous fluid. The author has an hindex of 10, co-authored 17 publications receiving 222 citations. Previous affiliations of Swati Garg include University Health Network.
Papers
More filters
Journal ArticleDOI
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux,Mihaela C. Cristea,Jeff Bruce,Swati Garg,Michael Cabanero,Gina Mantia-Smaldone,Alexander B. Olawaiye,Susan Ellard,Johanne I Weberpals,Andrea E. Wahner Hendrickson,Gini F. Fleming,Stephen Welch,Neesha C. Dhani,Tracy Stockley,Prisni Rath,Katherine Karakasis,Gemma N Jones,Suzanne Jenkins,Jaime Rodriguez-Canales,Michael Tracy,Qian Tan,Valerie Bowering,Smitha Udagani,Lisa Wang,Charles A. Kunos,Eric Chen,Trevor J. Pugh,Amit M. Oza +27 more
TL;DR: In this paper, the Wee1 inhibitor combined with gemcitabine was evaluated in patients with high-grade serous ovarian cancer, a TP53-mutated tumour type with high replication stress.
Journal ArticleDOI
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux,Stephanie Lheureux,Ana Oaknin,Swati Garg,Jeff Bruce,Ainhoa Madariaga,Neesha C. Dhani,Neesha C. Dhani,Valerie Bowering,Justin White,Sarah Accardi,Qian Tan,Marsela Braunstein,Katherine Karakasis,Iulia Cirlan,Stephanie Pedersen,Tiantiam Li,Lorena Fariñas-Madrid,Yeh Chen Lee,Zhihui Amy Liu,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Amit M. Oza,Amit M. Oza +24 more
TL;DR: This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis and the activity of cediranib–olaparib varied according to the PARPi resistance mechanism.
Journal ArticleDOI
Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing
Swati Garg,Teddy S. Nagaria,Blaise A. Clarke,Blaise A. Clarke,Orit Freedman,Zanobia Khan,Zanobia Khan,Joerg Schwock,Joerg Schwock,Marcus Q. Bernardini,Amit M. Oza,Kathy Han,Adam C. Smith,Adam C. Smith,Tracy Stockley,Tracy Stockley,Tracy Stockley,Marjan Rouzbahman,Marjan Rouzbahman +18 more
TL;DR: The genetic heterogeneity of gastric-type endocervical adenocarcinoma is shown with some potentially actionable molecular alterations, which highlights the importance of further molecular characterization for better identification of this rare entity, and hence better clinical management.
Journal ArticleDOI
A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium
Stephanie Lheureux,Anna V. Tinker,Blaise A. Clarke,Prafull Ghatage,Stephen Welch,Johanne I Weberpals,Neesha C. Dhani,Marcus O. Butler,Katia Tonkin,Qian Tan,David S.P. Tan,Kelly Brooks,Janelle Ramsahai,Lisa Wang,Nhu-An Pham,Patricia Shaw,Ming-Sound Tsao,Swati Garg,Tracy Stockley,Tracy Stockley,Tracy Stockley,Amit M. Oza +21 more
TL;DR: ENMD-2076 was well tolerated with main related grade 3 toxicities being hypertension, proteinuria, and diarrhea, and warrants further investigation as a potential predictive biomarker.
Journal ArticleDOI
Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics
Maksym Misyura,Tong Zhang,Mahadeo A. Sukhai,Mariam Thomas,Swati Garg,Suzanne Kamel-Reid,Tracy Stockley,Tracy Stockley,Tracy Stockley +8 more
TL;DR: A combined workflow using both platforms enabled successful molecular profiling of 96% (621/644) of tumor samples, and provided an approach for verification of somatic variants not amenable to verification by Sanger sequencing (<15% variant allele frequency).